secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001628280-23-017419
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine reports Q1 net loss $39.4M, cash $263M; nominates first development candidate PM359 for CGD
--------------------------------------------------------------------------------

- Net loss of $39.4M for Q1 2023 vs $23.8M in Q1 2022; R&D expenses $30.9M.
- Cash, cash equivalents, investments and restricted cash $263.0M as of March 31, 2023; runway into 2025.
- Appointed Jeff Marrazzo (former CEO of Spark Therapeutics) to Board of Directors.
- U.S. PTO issued second patent (No. 11,643,652) and allowed third patent application for Prime Editing.
- Plans to initiate IND-enabling studies for PM359 in CGD in 2023; first IND filing as early as 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000162828023017419/0001628280-23-017419-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000162828023017419/prme-20230511.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-017419

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer